The rise of cell and gene therapies comes with unique supply chain challenges, from manufacturing to distribution. We look at some of the tech solutions that could help smooth the complex development process.
One major challenge for the biopharma industry is developing and scaling advanced medicines efficiently.
In recent years, an increasing number of cell and gene therapies have been approved, providing new ways to tackle complex diseases like cancer. For example, 2017 saw the approval of Novartis’ CAR-T cell therapy, Kymriah, for an aggressive blood cancer. In the same year, Kite Pharma and Spark Therapeutics won similar approvals.
This growing category of cell and gene therapies — which has seen rising media interest — targets the root cause of a given disease specific to each patient, as opposed to many current treatments that target symptoms.